泰恩康拟开展外汇套期保值业务 最高合约价值不超4000万元

Core Viewpoint - Guangdong Taiankang Pharmaceutical Co., Ltd. has announced the approval of a foreign exchange hedging business to mitigate foreign exchange risk, with a maximum contract value of 40 million RMB or equivalent foreign currency per trading day [1][2]. Group 1: Business Overview - The primary purpose of the foreign exchange hedging business is to avoid and prevent foreign exchange rate fluctuations that could negatively impact the company's profits and shareholder equity [2]. - The hedging transactions will be limited to major settlement currencies used in the company's operations, including USD, EUR, and JPY [2]. - The company has set dual limits for the hedging business: a maximum contract value of 40 million RMB or equivalent foreign currency per trading day and a maximum margin and premium of 10 million RMB or equivalent foreign currency [2]. - The authorization for these limits is valid for 12 months from the board's approval date and can be reused within this period [2]. Group 2: Approval Process - The hedging proposal was approved by the company's board of directors on December 26, 2025, and had previously received approval from the audit committee [3]. - The proposal does not require submission to the shareholders' meeting as it falls within the board's decision-making authority [3]. - The board has authorized the chairman to make decisions and sign relevant documents within the approved limits, with the finance department responsible for executing the transactions [3]. Group 3: Risk Control - The company has identified four types of risks associated with the foreign exchange hedging business: market risk, operational risk, performance risk, and legal risk [4]. - To mitigate these risks, the company will implement several control measures, including establishing operational protocols, limiting transactions to actual business needs, and conducting transactions only with qualified financial institutions [4]. - The finance department will oversee daily operations and risk monitoring, with independent directors and the audit department having the authority to supervise compliance [4]. Group 4: Accounting Treatment and Funding Source - The company will account for the foreign exchange derivatives transactions in accordance with relevant accounting standards [5]. - All funding for the foreign exchange hedging business will come from the company's own funds, without involving raised funds or credit [5]. Group 5: Industry Analysis - As a pharmaceutical company, engaging in foreign exchange hedging is expected to stabilize cross-border operating costs, particularly amid increasing global exchange rate volatility, thereby enhancing the company's financial stability and supporting long-term development [6].